At a median follow-up of 53 months, the median PFS was not reached with KRd and was 48.8 months with VRd. Carfilzomib, lenalidomide, and dexamethasone (KRd) significantly prolonged progression-free ...
KRd showed superior PFS and deeper responses compared to VRd in newly diagnosed multiple myeloma patients, achieving higher complete response and MRD-negativity rates. The trial demonstrated ...
In the treatment of newly diagnosed multiple myeloma (MM), carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the long-held cornerstone regimen of ...
Carfilzomib-based quadruplet regimens are producing deep responses and high MRD negativity in NDMM, challenging bortezomib-based standards. KRd regimens show strong activity in both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results